Corxel is advancing its oral obesity drug **CX11**, a GLP-1 receptor agonist (GLP-1RA), into Phase III trials following positive Phase II results. The drug demonstrated weight loss of up to **11.5%** in patients with obesity. The company now aims to further validate its efficacy in larger-scale testing.
Corxel Pharmaceuticals reports its Phase 2 trial of **CX11** meets primary endpoints in obese and overweight U.S. adults, achieving up to **11.5% weight loss** over **36 weeks**. The drug demonstrates sustained weight reduction without evidence of plateauing. The trial evaluates safety and efficacy in a patient population facing rising obesity-related health challenges.
Corxel’s obesity treatment **CX11** achieves up to **11.5% weight loss** in participants after **36 weeks** in a Phase 2 trial. The drug targets adults classified as obese or overweight, meeting all primary trial endpoints. Early results suggest potential efficacy in addressing obesity through clinical testing.
Corxel secures **$287 million** in Series D funding to advance an **oral GLP-1 obesity treatment** licensed from China’s **Vincentage**. The company claims the pill delivers weight-loss results comparable to injectable GLP-1 therapies. Development will focus on scaling production and clinical validation.
